SECOND Gynaecological Cancer Academy

WORKSHOP

Paris, September, 6th 2013
Hotel Lutétia - Concorde Paris, “Pompéien” Meeting Room
45 Boulevard Raspail - 75006 Paris - France

08.00 / 08.05  WELCOME
Prof. Éric Pujade-Lauraine. Hôpital Hôtel-Dieu, Paris (France)

08.05 / 08.30  SUM-UP OF VISIONS AND MISSIONS
YT representative

08.30 / 9.30  WHAT IS ENGOT?
WHAT IS GCIG?
Q&A session/discussion
Prof. Andreas du Bois. Kliniken Essen Mitte, Essen (Germany)
Prof. Éric Pujade-Lauraine. Hôpital Hôtel-Dieu, Paris (France)

09.30 / 11.00  WORKSHOP SESSION I (4 TABLES): STATUS AND CRITICS OF EARLY DRUG DEVELOPMENT TRIALS IN ENGOT GROUPS. PART 1
At each table, pre-planned young trialist representatives present and discuss the design of one early drug planned/on-going in their group. Strength and Weakness. Summary and general discussions at the end.

FACILITATORS
Prof. Nicoletta Colombo. European Institute of Oncology, Milan (Italy)
Prof. Philipp Harter. Kliniken Essen Mitte, Essen (Germany)
Prof. Jonathan Ledermann. UCL Cancer Institute, London (UK)
Prof. Jacobus Pfisterer. Gynecologic Oncology Center, Kiel (Germany)
11.00 / 11.30  COFFEE

11.30 / 13.00  G4N TRANSLATIONAL RESEARCH ORGANISATION IN EUROPE
   FACILITATORS  Prof. Michael Birrer.  
Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston (USA)  
Prof. Mansoor Raza Mirza.  
Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

11.30 / 12.00  WHAT IS EUTROC?
   Prof. Jalid Sehouli.  
Universitätsmedizin Berlin, Charité, Campus Virchow Clinic, Berlin (Germany)

12.00 / 12.30  WHAT IS ENTRIGO?
   Prof. Martin Widschwendter.  
University College London - EGA Institute for Women’s Health, London (UK)

12.30 / 13.00  Q&A session/discussion

13.00 / 14.00  LUNCH

14.00 / 15.00  HOW TO INCORPORATE IN TRIALS PATIENT-REPORTED OUTCOMES. SESSION Nº2
   Q&A session/discussion
   Prof. Felix Hilpert.  
Universitätsklinikum Schleswig Holstein - Campus Kiel  
Klinik für Gynäkologie und Geburthilfe, Kiel (Germany)
   FACILITATORS  Dr. Eva Greimel.  
University of Graz, Graz (Austria)  
Prof. Sandro Pignata.  
National Cancer Institute Fondazione Pascale, Naples (Italy)

15.00 / 17.00  WORKSHOP SESSION II (4 TABLES): STATUS AND CRITICS OF TRANSLATIONAL STUDIES IN ENGOT GROUPS. PART 1
   At each table, 1 pre-planned young trialist representatives present and discuss the design of one translational study planned/on-going in their group. Strength and Weakness. Summary and general discussions at the end.
   FACILITATORS  Prof. Christian Marth.  
Medical University Innsbruck, Innsbruck (Austria)  
Prof. Andrés Poveda.  
Instituto Valenciano de Oncología, Valencia (Spain)  
Dr. Isabelle Ray-Coquard.  
Centre Léon Bérard, Lyon (France)  
Prof. Cristina Sessa.  
Ospedale San Giovanni, Bellinzona (Switzerland)

17.00  CLOSURE
   Prof. Éric Pujade-Lauraine.  
Hôpital Hôtel-Dieu, Paris (France)

This GCA initiative is possible thanks to a generous educational grant from Roche